Ginsenoside Rg3 endows liposomes with prolonged blood circulation and reduced accelerated blood clearance
Copyright © 2023. Published by Elsevier B.V..
PEGylated cholesterol-containing liposomes (Chol-PEG-lipo) have been widely used as a drug carrier for their good stealth property in blood circulation where cholesterol maintains the stability of the liposomal lipid bilayer and PEGylation endows liposomes with long circulation capability. However, cholesterol-related disadvantages and the accelerated blood clearance (ABC) phenomenon caused by PEGylation greatly limit the application of conventional stealth liposomes in clinic. Herein, ginsenoside Rg3 was selected to substitute cholesterol and PEG for liposomes preparation (Rg3-lipo). Rg3 was proved with similar liposomal membrane regulation ability to cholesterol and comparable long circulation effect to PEG. In addition, repeated administrations of Chol-PEG-lipo and Rg3-lipo were performed. The circulation time of the second dose of Chol-PEG-lipo was substantially reduced accompanied by a greatly increased accumulation in the liver due to the induction of anti-PEG IgM and the subsequent activated complement system. In contrast, no significantly increased level of relative plasma cells, IgM secretion and the complement activation in blood circulation was observed after the second injection of Rg3-lipo. As a result, Rg3-lipo showed great stealth property without ABC phenomenon. Therefore, developing liposomes utilizing Rg3 instead of PEG and cholesterol presents a promising strategy to prolong the blood circulation time of liposomes without triggering the ABC phenomenon and activated immune responses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:364 |
|---|---|
| Enthalten in: |
Journal of controlled release : official journal of the Controlled Release Society - 364(2023) vom: 15. Dez., Seite 23-36 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xia, Jiaxuan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.12.2023 Date Revised 08.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jconrel.2023.10.023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363557032 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363557032 | ||
| 003 | DE-627 | ||
| 005 | 20240308232117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jconrel.2023.10.023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1320.xml |
| 035 | |a (DE-627)NLM363557032 | ||
| 035 | |a (NLM)37863358 | ||
| 035 | |a (PII)S0168-3659(23)00673-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xia, Jiaxuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ginsenoside Rg3 endows liposomes with prolonged blood circulation and reduced accelerated blood clearance |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.12.2023 | ||
| 500 | |a Date Revised 08.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a PEGylated cholesterol-containing liposomes (Chol-PEG-lipo) have been widely used as a drug carrier for their good stealth property in blood circulation where cholesterol maintains the stability of the liposomal lipid bilayer and PEGylation endows liposomes with long circulation capability. However, cholesterol-related disadvantages and the accelerated blood clearance (ABC) phenomenon caused by PEGylation greatly limit the application of conventional stealth liposomes in clinic. Herein, ginsenoside Rg3 was selected to substitute cholesterol and PEG for liposomes preparation (Rg3-lipo). Rg3 was proved with similar liposomal membrane regulation ability to cholesterol and comparable long circulation effect to PEG. In addition, repeated administrations of Chol-PEG-lipo and Rg3-lipo were performed. The circulation time of the second dose of Chol-PEG-lipo was substantially reduced accompanied by a greatly increased accumulation in the liver due to the induction of anti-PEG IgM and the subsequent activated complement system. In contrast, no significantly increased level of relative plasma cells, IgM secretion and the complement activation in blood circulation was observed after the second injection of Rg3-lipo. As a result, Rg3-lipo showed great stealth property without ABC phenomenon. Therefore, developing liposomes utilizing Rg3 instead of PEG and cholesterol presents a promising strategy to prolong the blood circulation time of liposomes without triggering the ABC phenomenon and activated immune responses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Accelerated blood clearance (ABC) | |
| 650 | 4 | |a Complement activation | |
| 650 | 4 | |a Ginsenoside Rg3 | |
| 650 | 4 | |a IgM antibody | |
| 650 | 4 | |a Liposomes | |
| 650 | 4 | |a Long circulation | |
| 650 | 4 | |a Polyethylene glycol | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a ginsenoside Rg3 |2 NLM | |
| 650 | 7 | |a 227D367Y57 |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 700 | 1 | |a Chen, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Meichen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Anni |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Shiyi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ru |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Chunbo |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Xinnan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xinchun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jianxin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of controlled release : official journal of the Controlled Release Society |d 1996 |g 364(2023) vom: 15. Dez., Seite 23-36 |w (DE-627)NLM085820296 |x 1873-4995 |7 nnns |
| 773 | 1 | 8 | |g volume:364 |g year:2023 |g day:15 |g month:12 |g pages:23-36 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jconrel.2023.10.023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 364 |j 2023 |b 15 |c 12 |h 23-36 | ||